Wedbush maintains Neutral rating on Nektar Therapeutics, $50 price target

Wedbush maintained their Neutral rating on Nektar Therapeutics's stock with a price target of $50.00.The price target implies a downside of 18.0% from the Sep 22 close of $60.97.Key takeaways from the analyst noteConcerns Over Injection Site Reactions (ISRs): Nektar Therapeutics has faced skepticis…